Page 116 - Case Lab Case Analysis

that it would stock the generic version of Adrenaclick, a $110 EpiPen
alternative.

In all, the company's stock had gone from almost $58 a share in January
2016 to $38, a 34 percent drop, in January 2017.

Mylan Share Price

In June, 2017 the Institutional Shareholder Services (Mylan investment
funds) criticized Mylan for the "outsized compensation" of Mylan's

directors. The report urged Mylan's shareholders to vote against the re-
election of the company's directors after it paid Chairman Robert Coury
over $97 million in 2016 citing that the EpiPen price increases and
executive salaries caused “significant destruction in shareholder value”

and “long-term reputational damage.” The directors were re-elected.
Source: Egan, Matt. "EpiPen maker faces revolt over exec's $98 million pay
package". CNN Money

Competitor Comparisons

“Researchers analyzed more than 60,000 prescriptions for epinephrine
auto-injectors, written for 50,000 patients by more than 1,400 providers
nationwide, between January 2016 to February 2017. Since the start of
2016, they found, the percentage of epinephrine auto-injector
prescriptions that went to products other than EpiPen has more than
doubled.”
Source:https://insight.athenahealth.com/prescriptions-jump-epipen-alternatives